KORMAN HARRY
Known title: DirectorCIK: 0001197548
KORMAN HARRY's purchase track record
How the stock did after each of KORMAN HARRY's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since September 16, 2021
Stock higher 6 months later
20%
3 months: 60%
Median 6-month return
-7.2%
3 months: +4.0%
Beat the S&P 500
80%
median +2.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/26/2023 | VTRS | $171 | +32.3% | +30.5% | +22.0% |
| 3/16/2022 | VTRS | $2K | +4.0% | -7.2% | -9.4% |
| 3/4/2022 | VTRS | $12K | +16.0% | -5.3% | -9.3% |
| 12/16/2021 | VTRS | $2K | -17.6% | -19.6% | -21.5% |
| 9/16/2021 | VTRS | $2K | -4.1% | -21.0% | -1.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| VTRS | ▲ Buy | Option Exercise | 18,204 | $0 | 3/4/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 773 | $0 | 3/4/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 17,970 | $0 | 3/3/2024 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 885 | $0 | 3/3/2024 | View on chart |
| VTRS | ▲ Buy | Open Market | 19 | $171 | 10/26/2023 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 19,608 | $0 | 3/4/2023 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 705 | $0 | 3/4/2023 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 166 | $0 | 3/21/2022 | View on chart |
| VTRS | ▲ Buy | Open Market | 239 | $2K | 3/16/2022 | View on chart |
| VTRS | ▲ Buy | Open Market | 1,150 | $12K | 3/4/2022 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 13,996 | $0 | 3/2/2022 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 335 | $0 | 3/2/2022 | View on chart |
| VTRS | ▲ Buy | Open Market | 176 | $2K | 12/16/2021 | View on chart |
| VTRS | ▲ Buy | Open Market | 162 | $2K | 9/16/2021 | View on chart |
| VTRS | ▲ Buy | Open Market | 145 | $2K | 6/16/2021 | View on chart |
| VTRS | ▲ Buy | Open Market | 349 | $5K | 3/9/2021 | View on chart |
| VTRS | ▲ Buy | Open Market | 713 | $11K | 2/25/2021 | View on chart |
| VTRS | ▲ Buy | Open Market | 837 | $14K | 1/15/2021 | View on chart |
| VTRS | ▲ Buy | Open Market | 613 | $11K | 12/11/2020 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal
Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal. Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.